19 March 2019
Visiongain has published a new pharma report Global Anaesthesia Drugs Market 2019-2029: Local Anaesthesia, General Anaesthesia, Inhalation Anaesthesia, Intravenous Anaesthesia, Topical Anaesthesia, Benzocaine, Bupivacaine, Chloroprocaine, Lidocaine, Prilocaine, Ropivacaine, Desflurane, Dexmedetomidine, Midazolam, Propofol, Remifentanil, Sevoflurane and Others.
The Global Anaesthesia Drugs Market is estimated to grow at a CAGR of 3.9% from 2019 to 2024, dominated by the local anaesthesia submarket.
The global anaesthesia drugs market is projected to grow at lucrative rate during the forecast period owing to a rising number of surgical procedures globally, developing healthcare infrastructure in emerging economies, and growing number of geriatric population.
This report profiled the selected companies: AbbVie, AstraZeneca, Aurobindo Pharma, Baxter International, Inc., Fresenius Kabi, Hameln Pharmaceuticals and others.
The lead analyst commented that "The intravenous route is the most commonly used route of administration owing to its high effectiveness during critical surgeries, its high adoption in hospitals, and availability of advanced intravenous drugs which cater the need of surgeons. However, inhalation route of administration is projected to grow at the fastest rate owing to its growing application during the most critical as well as simple surgeries as the depth of inhaled anaesthesia is easy to control and advent from anaesthetic is rapid with minimum deleterious after effects."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Emerging markets offer many benefits for companies looking to conduct clinical trials, including large patient population and lower trial costs.
18 April 2019
The biosimilars landscape will likely to undergo great changes in the future as the market starts to mature.
17 April 2019
A major restraint in the global drug discovery outsourcing market comes from the fact that it is quickly becoming saturated, with many contract research organisations offering poorly differentiated services.
16 April 2019
The dermatological drugs market has in the past been the domain of small and medium-sized pharma companies specialising in dermatology and perhaps a few other therapeutic areas.